Skip to content
Buy This GLP
← Research
Safety

Do GLP-1 Drugs Cause Erectile Dysfunction? What Studies Found

A diabetes records study, a dulaglutide trial analysis and a semaglutide weight-loss study measured different aspects of erectile function.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Erectile dysfunction, vs DPP-4 drugs1.0before bias calibration1.26after bias calibrationno longer significantTang study of men with type 2 diabetes.

The evidence on erectile dysfunction (ED) is less clear than it is for common GLP-1 side effects such as nausea. The studies examined different drugs and groups of men. They also measured different things, from diagnoses in medical records to scores on an erectile function questionnaire.

What did researchers find in men with type 2 diabetes?

A U.S. medical record study compared 4,910 men who started a GLP-1 drug with 5,524 who started a DPP-4 inhibitor. ED was recorded at 35.2 versus 28.0 cases per 1,000 person-years. The weighted hazard ratio was 1.26 (95% CI 1.08 to 1.46) [1].

The authors also checked their method against outcomes the drugs would be unlikely to cause, a technique called negative control calibration. After calibration, the association was weaker and no longer statistically significant. Because the study relied on diagnosis codes, differences in how often ED was discussed or documented could affect the results.

What did a randomized trial measure?

An exploratory analysis of the REWIND trial included 3,725 men with type 2 diabetes who completed an erectile function questionnaire at baseline and at least once in follow-up. It found 21.3 first postrandomization cases of moderate or severe ED per 100 person-years with dulaglutide versus 22.0 with placebo (HR 0.92, 95% CI 0.85 to 0.99) [2]. The finding applies to dulaglutide in that trial population. It cannot establish the effect of semaglutide or tirzepatide.

What about semaglutide for weight loss?

A separate U.S. electronic record study matched 3,094 men aged 18 to 50 with obesity and no diabetes who were prescribed semaglutide to 3,094 who were not. It counted an ED diagnosis or a prescription for a PDE5 inhibitor, a type of ED medication. The combined outcome occurred in 1.47% versus 0.32% (RR 4.5, 95% CI 2.3 to 9.0) [3]. A prescription record cannot establish whether someone took semaglutide, and the study cannot show whether it caused the difference.

If you notice a change in erectile function after starting treatment, tell your prescriber when it began. The timing is one piece of information a clinician can use to evaluate it.

Frequently asked

Do GLP-1 drugs cause erectile dysfunction?
The evidence differs by drug, population and outcome. Medical record studies found more diagnoses or prescriptions in certain groups, but they could not establish causation. An exploratory randomized analysis found a slightly lower rate of moderate or severe ED with dulaglutide versus placebo.
Has a randomized trial measured erectile function on a GLP-1 drug?
Yes. An exploratory analysis of the randomized REWIND trial used a standardized questionnaire in 3,725 men with type 2 diabetes assigned to dulaglutide or placebo.

Sources

  1. [1] Tang H, Lu Y, Zhang B, Zhang D, Asch DA, Chen Y (2026). GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation EClinicalMedicine. PMID 42005929
  2. [2] Bajaj HS, et al. (2021). Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial The Lancet Diabetes & Endocrinology. PMID 34153269
  3. [3] Able C, et al. (2025). Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study International Journal of Impotence Research. PMID 38778151

More in Safety